substitution for "narrow therapeutic index" (NTI) drugs

December 1997

The new generic warfarin is raising a big controversy about substitution for "narrow therapeutic index" (NTI) drugs.

It's true some drugs have a narrow range between doses that are subtherapeutic...and doses that are toxic. Warfarin is one.

There are others...carbamazepine...digoxin...levothyroxine...phenytoin...theophylline.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote